Strategic fit Access Scientific’s POWERWAND midline and CVC WAND products target vascular access with a proven track record of zero BSIs over 23,000 catheter days, presenting a compelling case for hospitals prioritizing infection reduction and midline program adoption.

Hospital partnerships The company is already part of a larger ecosystem through the Smiths Medical acquisition, which can be leveraged to expand hospital network introductions, joint sales motions, and integrated product offerings to drive broader adoption.

Clinical evidence Extensive published data showing zero CRBSI across significant catheter-day deployments can be used in value-based selling with infection-control committees and procurement teams seeking measurable patient-safety improvements.

Regulatory edge FDA-cleared high-flow, power-injectable POWERWAND EDC and air-competent peelable introducer in CVC WAND position the products as differentiated solutions, enabling conversations about streamlined procedures and reduced procedural risk.

Growth levers Recent financing and ongoing marketing/sales expansion opportunities, combined with a scalable technology platform, indicate potential for channel sales with distributors and hospital systems aiming to modernize vascular access inventories.